生血合剂联合骨髓腔输血给药治疗再生障碍性贫血研究

发布时间：2018-05-28 11:35

本文选题：再生障碍性贫血 + 生血合剂　；参考：《中国实验血液学杂志》2017年05期

【摘要】：目的:研究生血合剂联合骨髓腔输血给药治疗再生障碍性贫血的疗效及安全性。方法:2011年至2015年,陕西医大血液病研究院对收住的53例再生障碍性贫血(脾肾两虚证)患者应用生血合剂200 ml,口服,2/d;司坦唑醇2 mg,3/d;吗替麦考酚酯成人1.0 g,2/d;骨髓腔输注:重组人红细胞生成素10000 U、重组人粒细胞刺激因子450μg、重组人白介素-11 4.5 mg、地塞米松注射液20 mg,骨髓腔注射,1周1次,共4次。治疗1月,观察血象和骨髓。出院后巩固治疗3-6个月,观察疗效,随访1年以上。结果:治疗1个月,基本治愈40例(75.47%)、缓解8例(15.09%);Hb、WBC及Plt与治疗前对比,均有显著好转(P0.01),有效率90.57%(48例);骨髓增生活跃者46例(86.79%),与治疗前9例(16.98%)相比,有好转(P0.05);治疗3-6个月,基本治愈40例(75.47%),缓解8例(15.09%),明显进步3例(5.66%)、无效2例(3.77%),基本治愈率和缓解率90.57%(48/53例),明显进步率5.66%,总有效率96.23(51/53例),治疗后检查无明显毒副作用。随访1年无复发。结论:生血合剂联合骨髓腔输血给药,是一种较好的治疗方法。
[Abstract]:Objective: to study the efficacy and safety of postgraduate blood mixture combined with intramedullary blood transfusion in the treatment of aplastic anemia. Methods: from 2011 to 2015, The Institute of Hematology, Shaanxi Medical University, applied 200 ml of Shengxue mixture to 53 patients with aplastic anemia (spleen and kidney deficiency syndrome), orally for 2 / d; 2 mg / d for Stanzolol; 1. 0 g / 2 / d for adults; 1. 0 g / 2 / d for adults; and 1. 0% / d for adult patients with mycophenolate mofetil; intramedullary infusion: recombinant human red fine 10000 U, 450 渭 g of recombinant human granulocyte stimulating factor, 4.5 mg of recombinant human interleukin-11, 20 mg of dexamethasone injection, once a week by intramedullary injection. A total of 4 times. One month after treatment, blood and bone marrow were observed. The curative effect was observed and followed up for more than 1 year. Results: after one month of treatment, 40 cases were basically cured, 40 cases were cured, 8 cases were relieved and 15.09 cases were relieved. Compared with before treatment, there was a significant improvement in P0.01C and Plt, the effective rate was 90.577.48 cases, 46 cases were active in bone marrow hyperplasia, compared with 9 cases (16.98 cases) before treatment, the improvement was P0.05, and the treatment was 3-6 months. 40 cases were basically cured, 8 cases were relieved, 3 cases were improved 5.66%, 2 cases were ineffective, the basic cure rate and remission rate were 90.57 / 48 / 53 cases, the improvement rate was 5.66%, the total effective rate was 96.2351% / 53 cases, and there were no obvious side effects after treatment. There was no recurrence after 1 year follow-up. Conclusion: Shengxue mixture combined with bone marrow transfusion is a better treatment.
【作者单位】：陕西医大血液病研究院;
【分类号】：R556.5

【相似文献】